DAVID GRANOVSKY

Posts Tagged ‘risk’

Influential research misses financial conflicts | Reuters

In BUSINESS OF STEM CELLS on March 9, 2011 at 12:40 pm

A pharmacy employee dumps pills into a pill counting machine as she fills a prescription while working at a pharmacy in New York December 23, 2009. REUTERS/Lucas Jackson

By Frederik Joelving

NEW YORK | Wed Mar 9, 2011 1:51am EST

NEW YORK (Reuters Health) – Scientists who review large sets of drug trials for medical journals often ignore financial conflicts that might warp the evidence, according to a study out Tuesday.

That’s more than just an academic problem, experts say, because the reviews are considered just about the strongest evidence that medical science can muster.

“It influences how physicians make decisions and how guideline panels come up with their guidelines,” said Brett D. Thombs, of McGill University and the Jewish General Hospital in Montreal, whose findings are published in the Journal of the American Medical Association (JAMA).

Thombs’ team found that of 29 reviews, or “meta-analyses,” of earlier drug trials — culled from top journals like JAMA and The Lancet — only two reported who had funded the original trials included in the review.

And none of the reviews mentioned whether the authors reporting on those trials had been paid by drugmakers.

Such financial ties have been linked to research inflating the benefits of new drugs and downplaying the risks, said Thombs.

 

Influential research misses financial conflicts | Reuters.

Advertisements

FDA Warns about Increased Risk of Muscle Injury with Zocor

In OFF THE BEATEN PATH on March 24, 2010 at 8:14 pm

FDA NEWS RELEASE

For Immediate Release: March 19, 2010

Media Inquiries: Elaine Gansz Bobo, 301-796-7567; elaine.bobo@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA

FDA Warns about Increased Risk of Muscle Injury with Zocor

Highest approved dose of cholesterol-lowering medication could cause harm to muscles

The U.S. Food and Drug Administration today warned patients and healthcare providers about the potential for increased risk of muscle injury from the cholesterol-lowering medication Zocor (simvastatin) 80 mg. Although muscle injury (called myopathy) is a known side effect with all statins, today’s warning highlights the greater risk of developing muscle injury, including rhabdomyolysis, for patients when they are prescribed and use higher doses of this drug. Rhabdomyolysis is the most serious form of myopathy and can lead to severe kidney damage, kidney failure, and sometimes death.

“Review of simvastatin is part of an ongoing FDA effort to evaluate the risk of statin-associated muscle injury and to provide that information to the public as it becomes available,” said Eric Colman, M.D., Deputy Director of FDA’s Division of Metabolism and Endocrinology Products (DMEP). “It’s important for patients and healthcare professionals to consider all the potential risks and known benefits of any drug before deciding on any one therapy or dose of therapy.”

Simvastatin is sold as a single-ingredient generic medication and as the brand-name Zocor. It also is sold in combination with ezetimibe as Vytorin, and in combination with niacin as Simcor.

FDA’s review of new information on the risk of muscle injury is derived from clinical trials, observational studies, adverse event reports, and prescription use data. The agency also is reviewing data from the SEARCH (Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine) trial, which evaluated major cardiovascular events, such as heart attack, revascularization and cardiovascular death, in patients taking 80 mg compared to 20 mg of simvastatin. SEARCH also included data on muscle injury in patients taking simvastatin…

via FDA Warns about Increased Risk of Muscle Injury with Zocor.

More Sex = Less Prostate Cancer Risk

In VICTORIES & SUCCESS STORIES on January 7, 2010 at 11:20 pm
Reduced Risk Prostate Cancer with Regular Ejaculation

From , former About.com Guide – Updated August 27, 2006

About.com Health’s Disease and Condition content is reviewed by the Medical Review Board

Filed In: Prostate health

How ejaculation helps reduce prostate cancer.
An epidemiological study of 30,000 American men by Michael Leitzman, a cancer researcher at the National Cancer Institute in Bethesda, Maryland, has found that men who enjoy an active sex life do not risk prostate cancer in later life.

There has been a suggested link with greater sexual activity and increased incidents of prostate cancer in previous scientific data because of the link with the male hormone testosterone and its effect on promoting cancer cell growth.

Leitzmann’s findings were that men who ejaculate between 13 and 20 times a month had a 14% lower risk of prostate cancer that men who ejaculated on average, between 4 and 7 times a month for most of their adult life. Men who ejaculated upwards of 21 times a month had a 33% lower lifetime risk of prostate cancer than the baseline group.

Ejaculation Frequency and Subsequent Risk of Prostate Cancer. Michael F. Leitzmann, MD; Elizabeth A. Platz, ScD; Meir J. Stampfer, MD; Walter C. Willett, MD; Edward Giovannucci, MD JAMA. 2004;291:1578-1586

%d bloggers like this: